I want to tell you about a pharmaceutical sales representative I observed last month.
She walked into a pharmacy in Pretoria at 9:14 AM. She didn’t carry a product binder. She didn’t ask to speak with the pharmacist about a promotional offer. She didn’t mention a single product feature.
Instead, she opened her tablet, showed the pharmacist a dashboard, and said: “You’ve lost 23% of your diabetic patient base over the past four months. I can see exactly where they’re going, and I have a plan to bring them back.”
The pharmacist put down what he was doing. The conversation lasted 47 minutes.
She walked out with the largest order that pharmacy had placed in three years.
This is the pharmaceutical representative of 2030. And she’s not selling. She’s conducting.
The Orchestra Problem
Here’s a number that should concern every pharmaceutical commercial director in Africa: 10x.
That’s the typical variance between the best and worst performing representatives in a pharmaceutical sales force. Your top rep outsells your bottom rep by a factor of ten. Same products. Same territories. Same training. Same incentive scheme.
When I share this number with executives, they nod knowingly. They’ve seen it. They’ve tried to fix it. They’ve invested in training programmes, coaching initiatives, performance management systems. Some have even resorted to mass terminations and rebuilds.
Nothing works. Not permanently.
And here’s why: they’re treating a systems problem as a people problem.
The 10x variance isn’t about talent. It’s about what happens before the rep walks through the door.
Think about it this way. An orchestra doesn’t succeed because it recruits the best individual musicians. An orchestra succeeds because every musician plays from the same score, follows the same conductor, and arrives prepared for the same performance.
Your sales force is an orchestra playing without a conductor. Each musician is reading a different score. Some are playing last year’s music. Others are improvising. A few are playing in the wrong key entirely.
The result? Noise. Expensive noise.
What the Research Actually Says
I’ve spent the past two decades reading what academics have discovered about sales performance. Not the airport bookstore variety. The peer-reviewed, meta-analysed, replicated findings from journals most pharmaceutical executives have never heard of.
Here’s what they found.
Verbeke, Dietz, and Verwaal (2011) conducted a comprehensive meta-analysis of sales performance drivers. They examined studies spanning 26 years and identified the five factors that actually predict sales success. The strongest predictor? Selling-related knowledge (β = .28). Second strongest? Degree of adaptiveness (β = .27).
Not personality. Not charm. Not even experience.
Knowledge and adaptation. The ability to know things the customer doesn’t, and the ability to change approach based on what you learn.
Franke and Park (2006) analysed 155 samples representing more than 31,000 salespeople. They found that adaptive selling behaviour increases self-rated, manager-rated, AND objective performance measures. Not one. All three.
Vinchur and colleagues (1998) discovered something that should reshape how we recruit: the conscientiousness facet of “achievement striving” correlates with objective sales performance at r = .41. That’s a correlation stronger than most pharmaceutical interventions achieve in clinical trials.
But here’s the finding that changed how I think about this industry entirely.
General cognitive ability, the thing we measure in aptitude tests and assume predicts everything, correlated with objective sales at r = .04.
Point zero four.
Essentially zero.
Intelligence doesn’t predict sales performance. Knowledge does. Adaptation does. Structured discipline does.
So why do most pharmaceutical companies still hire based on interview impressions, train based on product features, and measure based on call quantity?
Because they haven’t built the system that makes knowledge and adaptation possible.
The Rep as Conductor
In 2019, I stood in front of a whiteboard in our Johannesburg office and drew a picture that would become the foundation of everything Herbst Group does.
On the left side, I drew the traditional pharmaceutical representative: a messenger carrying information from the company to the customer. Arrow pointing one direction. Product knowledge in. Prescription hopefully out.
On the right side, I drew something different: a figure standing at the centre of a complex web. Information flowing in from multiple sources. Insights flowing out to multiple stakeholders. The rep wasn’t carrying messages. The rep was coordinating value.
Like a conductor in front of an orchestra.
The rep doesn’t play every instrument. The rep ensures every instrument plays at the right time, in the right key, for the right audience. The rep arrives prepared because someone else has already analysed the score. The rep delivers a performance, not a pitch.
We called it the Herbst Conductor™ model. And it works.
Here’s why.
The traditional pharmaceutical rep spends Monday morning planning the week. Pulling data. Analysing spreadsheets. Identifying which customers to see. Building call plans. This takes two to four hours of prime selling time every single week.
The Conductor rep receives a notification every Monday at 7 AM. It contains:
- A prioritised list of exactly which customers to see, ranked by opportunity size
- Specific product recommendations for each customer, based on their purchasing patterns
- Early warning alerts for accounts showing decline
- Performance context showing how the rep is tracking against benchmarks
The Conductor rep starts selling at 8 AM. The traditional rep starts selling at noon.
Multiply that difference across 200 selling days per year. Multiply it across a field force of 50 reps. You’ve just created the equivalent of 25 additional full-time selling resources without hiring anyone.
That’s not theory. That’s mathematics.
The Technology Stack That Makes Conducting Possible
I need to be specific here, because specificity is what separates consulting theatre from actual execution.
The Conductor model requires four components working in concert:
First: Transaction Intelligence.
We built a platform called SNIPER™ (Sales Navigation Intelligence Platform Enabling Results). It ingests 12 to 24 months of transaction data, applies pattern recognition algorithms, and outputs prescriptive actions.
SNIPER™ identifies what we call “Hidden Champions”: customers with high potential who are currently under-served. It flags declining accounts before they churn completely. It recommends specific products for specific customers based on purchasing behaviour, not demographic assumptions.
Most importantly, SNIPER™ reveals where revenue hides and where it leaks. In one recent engagement, we identified R47 million in annual revenue that was being lost through coverage gaps. The client’s best regional manager had no idea it was happening.
Second: Geographic Intelligence.
Her-Zone™ integrates 79 data layers: healthcare infrastructure, disease surveillance, demographics, commercial zones, travel patterns. Built from South African government sources and overlaid on commercial customer data.
When a Conductor rep opens Her-Zone™, she doesn’t see a map. She sees opportunity density. She sees travel optimisation. She sees where competitors win by default because nobody bothered to show up.
Third: Weekly Delivery Mechanism.
Auto-Snipe™ takes the outputs from SNIPER™ and Her-Zone™ and delivers personalised weekly intelligence to every rep in the field. Right customers. Right products. Right conversation. Every Monday.
The rep doesn’t analyse data. The rep receives insights. The rep acts.
Fourth: Real-Time Visibility.
FARM™ (Field Activity Resource Management) provides executives with live revenue trends, customer health monitoring, and rep productivity tracking. No more waiting for month-end. No more manually compiled reports. No more surprises.
When these four components work together, something remarkable happens. The variance between top and bottom performers shrinks. Not because the bottom performers suddenly become talented. Because the bottom performers finally have access to the same intelligence the top performers were generating through intuition and extra effort.
We don’t make bad reps good. We make the system fair.
The 2030 Representative in Practice
Let me paint a more complete picture of what pharmaceutical selling looks like when the Conductor model is fully operational.
It’s 6:47 AM on a Monday in April 2030. A pharmaceutical representative named Thandi opens her phone while drinking coffee. A notification from Auto-Snipe™:
“Priority call this week: Medi-Rite Pharmacy, Sandton. Account has declined 31% over six months. Owner purchasing competitor products in categories where you have therapeutic superiority. Opportunity value: R340,000 annually. Recommended approach: Clinical efficacy data for Product X. Owner responds to evidence-based arguments. Last positive interaction: August 2029.”
Thandi doesn’t need to pull reports. She doesn’t need to analyse spreadsheets. She doesn’t need to guess.
She arrives at Medi-Rite at 10:30 AM. She doesn’t open with “How’s business?” She opens with: “Johannes, I noticed something concerning in your purchasing patterns, and I wanted to talk through what might be happening.”
Johannes, the owner, looks up. Most reps ask him to stock more product. This one is asking about his business.
Thandi continues: “You’ve moved about R28,000 per month to a competitor in a category where our clinical outcomes are actually stronger. I’m curious whether that was a deliberate choice or whether something went wrong on our end.”
Johannes puts down his pen. The conversation has started differently than any rep conversation in his memory.
It turns out there was a delivery issue six months ago. A complaint that wasn’t resolved. A relationship that eroded through negligence, not competition.
Thandi pulls up Her-Zone™ on her tablet. She shows Johannes the patient demographic data for his catchment area. She shows him the disease prevalence. She shows him, with specificity, why his location is ideal for the therapeutic category they’re discussing.
Then she shows him clinical evidence. Not marketing materials. Evidence.
By the end of the conversation, Johannes has agreed to a trial order. Not because Thandi pushed. Because Thandi knew things Johannes didn’t, and those things were genuinely useful to his business.
Thandi leaves at 11:47 AM. Total time invested: 77 minutes. Value secured: R340,000 in recovered annual revenue, plus a relationship repaired.
The traditional rep would have made five calls in the same time. Shallow calls. Transactional calls. Calls that create activity reports but not business outcomes.
The Conductor made one call. It counted.
The Results (Because That’s What Actually Matters)
I could fill this article with philosophy. I won’t. Here’s what we’ve observed across our client engagements:
Sales Force Effectiveness Improvement: clients typically see 15-30% within 90 days of full deployment. Not through training. Through intelligence.
Coverage Efficiency Improvement: 15-30% when territory structure is redesigned around customer potential rather than geographic convenience.
Wasted Call Activity Reduction: 20%+ in the first month when calling on the right customers replaces equal-treatment assumptions.
Client ROI: 6-39X documented return on investment across our active partnerships.
Time to Value: 90-120 days from engagement start to first measurable outcome.
And here’s what I’m most proud of: ongoing partnerships. Not weeks. Not quarters. Our clients stay because the systems work.
We don’t do projects. We build systems that keep working after we leave.
Why Most Pharmaceutical Companies Won’t Do This
I want to be direct about something: most pharmaceutical commercial directors will read this article, nod in agreement, and change nothing.
Here’s why.
The Conductor model requires honesty about current performance. It requires admitting that call quantity reports are vanity metrics. It requires acknowledging that the territory structure inherited from a predecessor might be fundamentally broken. It requires confronting the possibility that some of your best performers are simply working harder, not smarter, and that advantage will disappear the moment they leave.
Most organisations aren’t ready for that conversation.
They prefer the comfortable fiction that training programmes will fix performance problems. That incentive scheme tweaks will close the 10x gap. That next quarter’s market research will finally reveal the insight they’ve been missing.
It won’t.
The insight isn’t missing. The system is missing.
And building the system requires investment, disruption, and leadership. Three things in perpetually short supply.
The Conductor Model and Human Dignity
I want to address an objection I hear occasionally: “Aren’t you reducing sales professionals to automatons? Where’s the human skill?”
The opposite is true.
The traditional model reduces sales professionals to message carriers. Walk in, recite features, leave samples, record the call. That’s not a profession. That’s a delivery service with a bonus structure.
The Conductor model elevates sales professionals to consultants. Arrive informed. Listen actively. Adapt continuously. Deliver genuine value. Build relationships that compound over years.
The Conductor rep thinks. The Conductor rep advises. The Conductor rep exercises judgment.
The automation isn’t replacing human capability. The automation is creating space for human capability to matter.
Consider what happens when a rep arrives at a customer without adequate preparation. She improvises. She relies on rapport. She talks about weather and sports and children. She mentions product features when the conversation allows. She hopes something sticks.
That’s not consultative selling. That’s expensive socialising.
When the same rep arrives with intelligence, something different becomes possible. She can ask informed questions. She can offer insights the customer lacks. She can position herself as a resource worth 47 minutes of undivided attention rather than a distraction to be politely tolerated.
Kahneman and Tversky won a Nobel Prize for demonstrating that human beings are predictably irrational. We overweight certain outcomes. We feel losses twice as intensely as equivalent gains. We anchor on irrelevant information.
The Conductor model doesn’t fight these tendencies. It accounts for them. When a rep knows a customer is facing a 31% decline, she can frame recovery as loss prevention rather than sales growth. When a rep knows a competitor is winning through presence rather than superiority, she can target that specific vulnerability.
The psychology is built into the system. The rep doesn’t need to remember the research. The rep needs to follow the plan.
What Changes by 2030
Let me make some specific predictions for pharmaceutical commercial operations in 2030. Not speculation. Extrapolations from trends we’re already observing.
Prediction One: Call quantity metrics will disappear. The organisations still measuring sales representatives by number of calls will be the organisations losing market share. Call quality, measured through outcome tracking, will replace call quantity entirely.
Prediction Two: Territory design will become continuous. Static annual territory reviews will give way to dynamic rebalancing based on real-time opportunity data. Territories will flex monthly, not annually.
Prediction Three: AI will handle preparation, humans will handle relationships. The insight generation currently requiring specialist analysts will be fully automated. Representatives will receive complete customer intelligence before every interaction. Their value will come from what they do with that intelligence, not from gathering it.
Prediction Four: The 10x variance will become a 2x variance. Not because the bottom performers improve dramatically. Because the system stops handicapping them. When everyone plays from the same score, the differences become about execution, not access.
Prediction Five: Pharmaceutical companies will compete for Conductors. The representatives who can interpret intelligence, adapt approaches, and build trust will command premium compensation. The representatives who can only deliver messages will find their roles eliminated.
The Invitation
I’ve spent 3,800 words telling you what’s possible. Now let me tell you what I want.
I want pharmaceutical commercial directors to stop tolerating the 10x variance as inevitable. It isn’t. It’s a systems failure, and systems can be rebuilt.
I want field force leaders to measure what matters. Outcome per call, not calls per day. Revenue recovered, not samples distributed. Relationships deepened, not contacts logged.
I want sales representatives to demand better from their employers. Demand intelligence. Demand preparation. Demand the tools that allow professional skills to matter.
And I want the organisations who are ready to act, not just agree, to contact us.
We’ve built the Conductor model over two decades. We’ve tested it across 30+ organisations. We’ve refined it through ongoing partnerships with clients who stayed because the results kept coming.
We don’t promise transformation. We deliver documented improvements within 90 days.
That’s not marketing language. That’s our operating standard.
Final Thought
The pharmaceutical representative of 2030 will walk into a pharmacy and have a conversation that would be impossible today.
Not because she’s smarter. Not because she’s more charming. Not because she trained harder or cares more or has more experience.
Because she arrived prepared.
Because someone built the system that made preparation automatic.
Because the orchestra finally has a conductor.
The representative I described at the beginning of this article isn’t hypothetical. She’s real. She works for one of our clients. She closed the largest order in that pharmacy’s three-year history because she knew things the pharmacist didn’t, and those things were genuinely useful.
That’s not selling.
That’s conducting.
And by 2030, it will be the only way pharmaceutical commercial excellence happens.
Dieter Herbst is CEO of Herbst Group, a pharmaceutical commercial excellence firm with ongoing embedded partnerships. Herbst Group’s methodologies include SNIPER™, Her-Zone™, Auto-Snipe™, FARM™, and the Herbst Conductor™ Framework. Contact: herbstgroup.io
“Precision beats volume. Every time.”
Listen to This Article
The Pharmaceutical Representative of 2030
Written by
Dieter Herbst
CEO & Founder at Herbst Group. Working with pharmaceutical commercial leaders across South Africa, Kenya, and Brazil to transform sales force effectiveness through evidence-based approaches.
Connect on LinkedIn